Drug Profile


Alternative Names: 323U66; Amfebutamone; Amfebutamone SR; Aplenzin; Bupropion HCL SR; Bupropion hydrobromide; Bupropion hydrochloride; Bupropion hydrochloride SR; Bupropion XL; BVF 033; Elontril; Quomem; Wellbutrin; Wellbutrin SR; Wellbutrin XL; Wellbutrin XR; Zyban

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biovail Corporation
  • Developer GlaxoSmithKline; Valeant Pharmaceuticals International
  • Class Antidepressants; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Seasonal affective disorder; Smoking withdrawal
  • No development reported Obesity; Post-traumatic stress disorders; Social phobia

Most Recent Events

  • 17 Mar 2017 GlaxoSmithKline completes a phase III trial in Major Depressive Disorder in China (NCT02191397)
  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2016 GlaxoSmithKline completes a phase I pharmacokinetics trial in Healthy volunteers in China (PO, Controlled release) (NCT02698553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top